Figure 2From: Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human gliomaSLC22A18 expression in patients stratified by tumor grade and recurrence. (A) Semiquantitative analysis of SLC22A18 immunohistochemical staining in low grade (WHO I-II) glioma and high grade (WHO III-IV) glioma. (B) Semiquantitative analysis of SLC22A18 immunohistochemical staining in gliomas which recurred and those which did not recur within six months after surgery, P values compare overall SLC22A18 expression in each group.Back to article page